211 related articles for article (PubMed ID: 28477059)
1. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
3. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.
Wang Z; Ren ZG; Ma NY; Zhao JD; Zhang Z; Ma XJ; Long J; Xu J; Jiang GL
Radiat Oncol; 2015 Jan; 10():14. PubMed ID: 25575617
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
5. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.
Chang JS; Chiu YF; Yu JC; Chen LT; Ch'ang HJ
Cancer Res Treat; 2018 Apr; 50(2):562-574. PubMed ID: 28602054
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
[TBL] [Abstract][Full Text] [Related]
7. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Choi SH; Park SW; Seong J
Radiother Oncol; 2018 Nov; 129(2):340-346. PubMed ID: 30177371
[TBL] [Abstract][Full Text] [Related]
8. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.
Koom WS; Seong J; Kim YB; Pyun HO; Song SY
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1148-54. PubMed ID: 18760544
[TBL] [Abstract][Full Text] [Related]
9. Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer.
Kwak YK; Lee JH; Lee MA; Chun HG; Kim DG; You YK; Hong TH; Jang HS
Radiat Oncol J; 2014 Jun; 32(2):49-56. PubMed ID: 25061572
[TBL] [Abstract][Full Text] [Related]
10. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
11. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer.
Hiroshima Y; Fukumitsu N; Saito T; Numajiri H; Murofushi KN; Ohnishi K; Nonaka T; Ishikawa H; Okumura T; Sakurai H
Radiother Oncol; 2019 Jul; 136():37-43. PubMed ID: 31015127
[TBL] [Abstract][Full Text] [Related]
13. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
15. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
[TBL] [Abstract][Full Text] [Related]
17. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
19. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?
Wang JK; Hu HJ; Shrestha A; Ma WJ; Yang Q; Liu F; Cheng NS; Li FY
Oncotarget; 2017 Jul; 8(28):45335-45344. PubMed ID: 28484084
[TBL] [Abstract][Full Text] [Related]
20. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
